Clinical trials: Eating Disorder NOS
Binge-Eating Disorder
Reduction of the Speed of Eating as an Intervention in Obesity
Patients diagnosed with Binge Eating Disorder (BED) overeat food but, as opposed to patients with bulimia nervosa, they do not compensate for their increased food intake and therefore their body weight increases.
- Trial name
- NCT02381327
- Testing
- Mandometer
- Where
- Sweden
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- Mando Group AB
Eating Disorders, Binge Eating
Study of Efficacy and Safety of WELT-ED for Eating Disorder (WCTP-ED-B-01)
The purpose of this clinical trial is to evaluate the safety and efficacy of a digital therapeutic device (WELT-ED) based on Cognitive Behavioral Therapy (CBT) for the treatment of eating disorders.
- Conditions
- Eating Disorders, Binge Eating, Binge-Eating Disorder
- Trial name
- NCT06294353
- Testing
- WELT-ED (CBT based DTx), Standard Treatment
- Where
- 2 sites in South Korea
- Volunteers
- 134 people
- Sponsor
- WELT corp
Binge-Eating Disorder
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder
This is a Phase 3, multi-center, open-label and randomized withdrawal study to evaluate the long-term safety and efficacy of solriamfetol in the treatment of binge eating disorder (BED) in adults.
- Trial name
- NCT06878976
- Testing
- Solriamfetol
- Where
- 33 sites in United States
- Volunteers
- 236 people
- Sponsor
- Axsome Therapeutics, Inc.
Binge Eating Disorder
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The primary objective of the study is to demonstrate the efficacy of SPD489 compared with placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating Disorder at Visit 8 (Weeks 11 and 12) as measured by…
- Trial name
- NCT01718509
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 48 sites in United States, Germany
- Volunteers
- 390 people
- Sponsor
- Shire
Binge Eating Disorder
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The primary objective of the study is to demonstrate the efficacy of SPD489 compared with placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating Disorder at Visit 8 (Weeks 11 and 12) as measured by…
- Trial name
- NCT01718483
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 50 sites in United States, Germany and 2 more
- Volunteers
- 383 people
- Sponsor
- Shire
Eating Disorders
The Use of Smart Devices in Capturing Digital Biomarkers in Eating Disorders
This study aims to explore how smart devices can be used to monitor the health of individuals with eating disorders. Eating disorders are serious mental health conditions that impact both mental and physical health.
- Trial name
- NCT06544226
- Testing
- UH100
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- Univa Health
Obesity, Binge-Eating Disorder
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
The purpose of this study is to evaluate the safety and effectiveness of topiramate compared to placebo in reducing the number of binge days in patients with moderate to severe binge-eating disorder associated with obesity.
- Trial name
- NCT00210808
- Testing
- topiramate
- Volunteers
- 407 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Binge Eating Disorder
Open Label Extension in Adults With Binge Eating Disorder (BED)
To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults
- Trial name
- NCT01657019
- Testing
- Lisdexamfetamine dimesylate
- Where
- 89 sites in United States, Germany and 1 more
- Volunteers
- 604 people
- Sponsor
- Shire
Binge Eating Disorder
Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder
To better understand the potential benefits of psychedelics in overeating disorders, Tryp Therapeutics will conduct a safety and feasibility clinical trial using TRP 8802 among individuals with Binge Eating Disorder.
- Trial name
- NCT05035927
- Testing
- TRYP-0082, Psychotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- TRYP Therapeutics
Binge-Eating Disorder
A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
The primary objective of this study is to assess the efficacy of 2 doses of centanafadine sustained-release (SR) (200 milligrams [mg] and 400 mg total daily dose [TDD]) compared with placebo in adults with moderate to severe…
- Trial name
- NCT05113953
- Testing
- Centanafadine
- Where
- 25 sites in United States
- Volunteers
- 147 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Binge-eating Disorder
Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder
This study will check how and to whom Vyvanse is prescribed in Australia by retrospectively analyzing a prescription database with additional information provided by a physician survey.
- Trial name
- NCT04866043
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- Shire
Eating Disorders, Binge Eating Disorder
Optimizing a Smartphone Application for Individuals With Eating Disorders
This study will augment an existing mobile application for individuals with eating disorders by developing adaptive, tailored content targeting remediation of cognitive distortions.
- Conditions
- Eating Disorders, Binge Eating Disorder, Bulimia Nervosa
- Trial name
- NCT02503098
- Testing
- Recovery Record adaptive smartphone application, Recovery Record standard smartphone application
- Where
- 2 sites in United States
- Volunteers
- 3,340 people
- Sponsor
- Recovery Record Research
Binge Eating Behaviour, Binge Eating/Loss of Control Eating
Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway
The goal of this clinical trial is to thoroughly explore and ascertain the mechanism of action of the therapy with the EXOMIND (BTL-699-2) device in the treatment of food cravings (serving as an important precipitant to binge…
- Conditions
- Binge Eating Behaviour, Binge Eating/Loss of Control Eating, Food Craving
- Trial name
- NCT07024550
- Testing
- Treatment with BTL-699-2 device, Treatment with BTL-699-2 device with intensity below therapeutic threshold
- Where
- Czechia
- Volunteers
- 8 people
- Sponsor
- BTL Industries Ltd.
Binge Eating Disorder, Obesity
A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder
The purpose of this study is to examine the safety and efficacy of sibutramine in preventing binge eating episodes. Additionally the study aim is to evaluate the safety and efficacy of sibutramine in reducing body weight in…
- Trial name
- NCT00402584
- Testing
- sibutramine
- Volunteers
- 304 people
- Sponsor
- Abbott
Binge-Eating Disorder
Technology Assisted Treatment for Binge Eating Behavior
Binge-eating behavior is a central feature of eating disorders (e.g., binge-eating disorder, bulimia nervosa, anorexia nervosa-binge-eating/purging subtype) and is associated with higher rates of psychopathology, psychosocial…
- Trial name
- NCT05829941
- Testing
- Smartwatch app to deliver binge-eating CBT strategies, Reminder control condition
- Volunteers
- 30 people
- Sponsor
- HabitAware Inc.
Binge Eating
An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.
The purpose of this study is to evaluate the effectiveness and tolerability of topiramate compared to placebo in patients with binge eating disorder receiving Cognitive Behavior Therapy (CBT)
- Trial name
- NCT00307619
- Testing
- topiramate
- Volunteers
- 73 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Binge Eating, Binge-Eating Disorder
EXOMIND (BTL-995) for the Reduction of Binge-eating
The goal of this clinical trial is to evaluate if the treatment with the BTL-995-rTMS device is able to reduce binge eating in adults above the age of 22 years.
- Trial name
- NCT06894615
- Testing
- Treatment with BTL-995-rTMS
- Where
- Czechia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Binge Eating Disorder
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week
- Trial name
- BED (NCT01291173)
- Testing
- lisdexamfetamine dimesylate (SPD489)
- Where
- 31 sites in United States
- Volunteers
- 271 people
- Sponsor
- Shire
Binge Eating Disorder
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A study to evaluate a drug (dasotraline) on the safety, effectiveness and how well the body tolerates it, in adults with moderate to severe binge eating disorder
- Trial name
- NCT03107026
- Testing
- dasotraline 4mg, dasotraline 6mg
- Where
- 50 sites in United States
- Volunteers
- 491 people
- Sponsor
- Sumitomo Pharma America, Inc.
Binge-Eating Disorder
EXOMIND (BTL-995) for Reduction of Binge-eating
The goal of this clinical trial is to evaluate if the treatment with the BTL-995-rTMS device is able to reduce binge eating in adults above the age of 22 years.
- Trial name
- NCT06910592
- Testing
- Treatment with BTL-995-rTMS
- Where
- Bulgaria
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.